抗流感病毒药物神经氨酸酶抑制剂奥司他韦研究进展  

Research progress on osehamivir-one of influenza neuraminidase inhibitors

作　　者：张玲[1] 魏绍静[1] 

机构地区：[1]广州市第八人民医院研究所,516000

出　　处：《国际医药卫生导报》2011年第22期2718-2723,共6页International Medicine and Health Guidance News

基　　金：基金项目：广东省自然科学基金资助项目（8151006002000005）

摘　　要：高致病性禽流感H5N1病毒在亚州的爆发和2009新型H1N1病毒的全球性传播，提示设计与研发新型的抗流感药物尤为迫切。神经氨酸酶在病毒复制和传播中发挥重要作用，且活性中心高度保守，其抑制剂成为抗流感药物研发的热点。该文回顾了临床广泛使用的奥司他韦（osehamivir）药动学、药效学及耐药性方面的研究进展，为此药今后的临床应用提出建议。The outbreak of highly pathogenic avian influenza H5N1 in Asia and the global spread of new type 2009 H 1N 1, implies that to design and explore new anti-influenza drugs is quite urgent. Neuraminidase（NA） plays an important role in influenza virus reproduction and dissemination, further- more the active center of NA is highly conservative, so the research on influenza NA inhibitors has been greatly concerned. This article reviews the research progress on pharmacodynamics, phannacokinetics and drug resistance of oseltamivir, providing advices for its future application in clinic.

关 键 词：神经氨酸酶抑制剂 流感病毒 奥司他韦 研究进展 

分 类 号：R9[医药卫生—药学]